RAK-GOV-MEDIA-OFFICE
12.3.2024 14:33:29 CET | Business Wire | Press release
Steeped in 7,000 years of history, the UAE’s ‘Nature Emirate’ Ras Al Khaimah is undergoing an unprecedented period of economic growth, with tourism, real estate and sustainability taking center stage. Within this dynamic ecosystem, Ras Al Khaimah Art has flourished to become the Emirate’s landmark celebration of culture and the arts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312427377/en/
Featuring works from 107 local and international artists and welcoming 45,000 visitors from around the world, Ras Al Khaimah Art 2024 has successfully concluded its 12th edition at the restored Al Jazeera Al Hamra Heritage Village. Launching as a three-day art exhibition in 2013, Ras Al Khaimah Art has evolved into a month-long annual event and the UAE’s largest outdoor art festival, showcasing Ras Al Khaimah’s vibrant cultural heritage and reflecting the Emirate’s unprecedented cross-sector economic growth. (Photo: AETOSWire)
Inspired by the vision of H.H. Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, the festival was conceived to showcase the Emirate’s artistic talent and foster cultural exchange. Launching at Ras Al Khaimah’s National Museum in 2013 as a three-day exhibition, Ras Al Khaimah Art has evolved into a month-long annual event, welcoming 106 local and international artists from 35 countries in 2024, alongside 45,000 visitors.
Vision & Teamwork
Founding Executive Director of the Al Qasimi Foundation and Ras Al Khaimah Art organiser, Dr. Natasha Ridge acknowledged the event’s potential early on and explored avenues for expansion. During a visit to La Gacilly in France, she encountered a village transformed into an outdoor art gallery and envisioned a similar concept for Ras Al Khaimah Art: “I knew the perfect place.”
Listed on UNESCO’s tentative list of World Heritage Sites, Al Jazeera Al Hamra Heritage Village is the UAE’s last-surviving pearl-fishing village, representing centuries of architecture, trade and culture. Encompassing a fort, watchtowers, a mosque, souq and traditional dwellings, the magical site is defined by a labyrinth of stone alleyways and today, by Ras Al Khaimah Art.
“It’s not just an art festival, it’s also a historical site, which attracts a much wider audience,” says Dr. Ridge.
Ras Al Khaimah Art’s repertoire has expanded to include a range of artistic expressions, from workshops and film screenings to live performances and an art exploration program. “Last year, we saw 1000 students participate in workshops and tours. By connecting our youth with history and culture, we adopt a sustainable approach to the arts,” says Dr. Ridge.
Cultivating Global Connections
Ras Al Khaimah Art plays a pivotal role in promoting Ras Al Khaimah as a cultural destination. By providing a platform for local artists alongside international counterparts, Ras Al Khaimah Art also contributes to the cultural and economic progress of the UAE.
Read more: www.rakart.ae/2024-festival
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240312427377/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom